Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China.
Cancer Biomark. 2020;28(2):151-158. doi: 10.3233/CBM-191164.
The interest in plasma biomarkers has increased recently. Plasma exosome-derived microRNA-532 is aberrantly expressed in a variety of human cancers and has the prognostic value in many solid tumors. However, the prognostic impact of the expression value on AML remains unclear.
The aim of this study is to investigate the prognostic value of exosome-derived microRNA-532 in AML patients.
We performed the real-time PCR to quantify exosome-derived microRNA-532 in plasma of 198 AML patients. To assess the prognostic value, we performed Cox regression analyses in the context of well-established clinical and molecular markers. Cellular metabolic profile was conducted to help us understand the biological insight of its expression.
The expression level was not associated with white blood cell counts, age, FAB subtypes, cytogenetic risk groups and genes of FLT3-ITD, NPM1, CEBPA and DNMT3A mutations. Interestingly, high expressers had a favorable overall survival in the univariate analysis. This prognostic value was testified in the multivariate analysis. Moreover, up-regulation of miR-532 was negatively associated with cellular energy like fructose and glutamine.
We found plasma exosome-derived microRNA-532 can be used as a novel survival predictor for acute myeloid leukemia.
最近，人们对血浆生物标志物的兴趣有所增加。血浆外泌体衍生的 microRNA-532 在多种人类癌症中表达异常，并且在许多实体瘤中有预后价值。然而，其表达值对 AML 的预后影响尚不清楚。
本研究旨在探讨外泌体衍生的 microRNA-532 在 AML 患者中的预后价值。
我们通过实时 PCR 定量了 198 例 AML 患者血浆中的外泌体衍生的 microRNA-532。为了评估预后价值，我们在既定的临床和分子标志物的背景下进行了 Cox 回归分析。进行细胞代谢谱分析，以帮助我们了解其表达的生物学见解。
表达水平与白细胞计数、年龄、FAB 亚型、细胞遗传学危险组以及 FLT3-ITD、NPM1、CEBPA 和 DNMT3A 突变的基因无关。有趣的是，在单因素分析中，高表达者的总生存率较好。该预后价值在多因素分析中得到了验证。此外，miR-532 的上调与果糖和谷氨酰胺等细胞能量呈负相关。
我们发现血浆外泌体衍生的 microRNA-532 可作为急性髓细胞白血病的新型生存预测因子。
